Australia's Patrys soars on positive cancer drug pre-clinical data
17/10/2022 05:56
** Shares of antibody development company Patrys Ltd
PAB.AX jump as much as 5.3% to A$0.023, on track for their
biggest intra-day percentage change since Aug. 10
** Co says pre-clinical data for its cancer drug antibody
PAT-DX3 proved effective to cross the blood-brain barrier in
healthy animals urn:newsml:reuters.com:*:nASX9lrh40
** Says study supports the drug's potential to treat various
cancer-related neurological targets and conditions
** Shares hit their highest since Sept. 26
** More than 10 mln shares change hands, compared with the
30-day average volume of ~1.8 mln shares
** Stock down 48.7% this year, as of last close, vs a 9.2%
decrease in the benchmark S&P/ASX 200 index .AXJO
(Reporting by Roushni Nair in Bengaluru)
((Roushni.Nair@thomsonreuters.com;))